A promising path to fighting COVID and other coronaviruses may have been based on a serious mistake. Scientists had zeroed in ...

The COVID pandemic illustrated how urgently we need antiviral medications capable of treating coronavirus infections. To aid ...

The use of TNF-α inhibitors among patients with hidradenitis suppurativa did not affect seroconversion following mRNA vaccination for COVID-19.

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, designed to hinder the SARS-CoV-2 virus’s ability to replicate.

Since winter 2023–2024, Omicron JN.1 lineage strains of SARS-CoV-2, including the JN.1 and the KP.2 strain, have been widely circulating in the United States. Recommendations for the 2024–2025 ...

The trial’s two primary objectives were for the drug to show immune responses against the SARS-CoV-2 virus strain that causes COVID-19 and against both A and B influenza strains.

Pfizer Inc. has identified nonstructural protein 3 (nsp3; PLpro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 (COVID-19) infection.

Emerging severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron subvariants are considered antigenically distinct, defined by escape from neutralising antibodies. To assess the antigenic ...

Pfizer and BioNtech have announced positive topline data from a vaccine phase 1/2 study (NCT0T05596734), demonstrating immune response to influenza A, influenza B, and SARS-CoV-2 strains.

A Pfizer document submitted to the U.S. Federal Drug Administration describes a microscop7 study of the SARS-CoV-2 protein that used graphene oxide in one step, but the reference to that material ...